Specialties
- Hematology/Medical Oncology
Area of focus i
- Melanoma
- Kidney cancer (renal cancer)
- Sarcoma
Affiliated with
1240 S Cedar Crest Blvd
Suite 401
Allentown, PA 18103-6218
United States
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.
1240 S Cedar Crest Blvd
Suite 401
Allentown, PA 18103-6218
United States